The invention, as defined by the claims herein, was made by the parties to a Joint Research Agreement between Sorin Biomedica Cardio S.r.l. and Mayo Foundation for Medical Education and Research.
The present invention relates to instruments for the in situ delivery and positioning of implantable devices. In particular, the invention relates to the in situ delivery of expandable prosthetic cardiac valves.
There is much interest in the medical community in expandable prosthetic valves designed to be implanted using minimally-invasive surgical techniques (e.g., transthoracic microsurgery) or endovascular (i.e., percutaneous) techniques, which are less invasive than the surgical operations required for implanting traditional cardiac-valve prostheses. These expandable prosthetic valves typically include an anchoring structure or armature, which is able to support and fix the valve prosthesis in the implantation position, and prosthetic valve elements (e.g., leaflets or flaps), which are connected to the anchoring structure and are configured to regulate blood flow. One exemplary expandable prosthetic valve is disclosed in U.S. Publication 2006/0178740 A1,which is incorporated herein by reference in its entirety.
Expandable prosthetic valves enable implantation using various minimally-invasive and/or sutureless techniques. Various techniques are generally known for implanting such an aortic valve prosthesis and include percutaneous implantation (e.g., transvascular delivery through a catheter), dissection of the ascending aorta using minimally-invasive thoracic access (e.g., mini-thoracotomy), and transapical delivery in which the aortic valve annulus is accessed directly through an opening in or near the apex of the left ventricle. There is a need in the art for improved systems for delivering the valve prosthesis to an appropriate location in a patient's cardiovascular system.
The present invention, according to one embodiment, is a cardiac valve implantation system for implanting a cardiac valve prosthesis at an implantation site associated with a cardiac valve annulus. The system includes an expandable cardiac valve prosthesis including a plurality of radially expandable portions and a plurality of valve leaflets. It further includes a deployment instrument including a control handle and a plurality of independently operable deployment elements operable to deploy the plurality of radially expandable portions. The system also includes a delivery device adapted to provide a pathway from outside the patient's body for delivery of the deployment instrument to the implantation site. The delivery device is adapted to provide a de-aired, fluid-filled, or gas-filled environment surrounding the prosthesis.
The present invention, according to another embodiment, is a minimally-invasive method of implanting an expandable cardiac valve prosthesis at an implantation site. The method includes positioning the cardiac valve prosthesis in a deployment instrument including a carrier portion, substantially removing atmospheric air from the carrier portion, advancing the deployment instrument to the implantation site, and deploying the valve prosthesis at the implantation site. The method may include removing air from the carrier portion by filling the chamber with a fluid.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the invention is capable of modifications in various obvious aspects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
As shown in
The manipulation portion 3 may assume various configurations.
This configuration is adapted for use, for example, in the sutureless and the transapical implantation methods.
In one embodiment, the instrument 1 is adapted for use with a separate delivery tool. The instrument 1, for example, may be sized and shaped for delivery through a lumen of a tube or trocar during a “sutureless” or transapical delivery technique. Likewise, the instrument 1 may be adapted for delivery through a working lumen of a delivery or guide catheter. In this embodiment, for example, the operator may first deliver a guide catheter through the patient's vasculature to the implant site and then advance the instrument 1 through the lumen. According to another embodiment, the instrument 1 includes an axial lumen extending from a proximal end to a distal end. The lumen is sized to allow introduction and advancement of the instrument 1 over a previously-implanted guide wire. In other embodiments, other techniques known in the art are used to reach the implantation site from a location outside the patient's body.
As shown in
In yet an alternative embodiment, an optional micro-blood pump is operatively linked to the deployment elements 10 or 20 (or forms a part of the carrier portion 2, and serves to facilitate the movement of blood in a desired direction during the prosthesis placement procedure. The micro-blood pump can have a variable flow rate functionality to regulate blood flow as desired.
In an alternative embodiment (shown in
In yet another embodiment of the invention, the delivery instrument 1, including its various portions, is de-aired (i.e., atmospheric air is substantially removed), filled with a fluid (e.g. saline), or filled with an appropriate gas (e.g., carbon dioxide or nitrogen) prior to use. In one embodiment, the lumen of the delivery instrument, which may include a compressed prosthetic valve, is filled with a non-embolytic gas. This process eliminates the risk of an embolism occurring through the introduction of any of the portions described above directly into the beating heart of the patient. According to one exemplary embodiment of the present invention, the delivery instrument, in particular the manipulator portion 3, may include an injection port adapted to mate with a syringe adapted for delivering a fluid or a gas to the delivery instrument. The injection port may include a seal for maintaining fluid pressure in the lumen and may include on or more pressure regulation devices.
According to another exemplary embodiment, a vacuum may be applied to the delivery instrument via a manifold at the proximal end of the manipulator portion 3. The applied vacuum ensures that all oxygen has been evacuated from the delivery tool. Additionally, the carrier portion 2 and the prosthetic valve therein may be assembled and sealed under vacuum.
According to yet another exemplary embodiment, the delivery instrument may be assembled in an environment saturated with a fluid, such as saline, or a gas, such as CO2. For example, the carrier portion 2 and the prosthetic valve therein may be assembled in a saline or CO2 saturated environment such that the carrier portion 2 is filled with the fluid, while the prosthetic valve is loaded into the chamber or carrier portion of the delivery instrument. According to various embodiments, the fluid includes a drug (e.g., heparin) selected to assist with the delivery of the prosthesis. The drug may, for example, include any drug known to manipulate or enhance cardiac function. According to other embodiments, the fluid includes an electrolytic solution.
In the case of a cardiac valve prosthesis to be deployed at an aortic position, the inflow end IF of the prosthesis V is located in correspondence with the aortic annulus, thereby facing the left ventricle. The profile of the aortic annulus is shown schematically by the dashed lines A in
In one embodiment, the sheath 11 is movable in a distal-to-proximal direction, so that the sheath and thus the element 10 move or slide “backwards” with respect to the carrier portion 2. In a complementary manner, the sliding movement of the tendon 21 will take place in a proximal-to-distal direction, so that the tendon and thus the element 20 move or slide “forward” with respect to the carrier portion 2. In another embodiment, movement of the elements 10, 20 is obtained by manipulating rigid actuation members from the handle 4.
In yet a further embodiment, while the device 1 is shown as being manually operable by a user, it is within the spirit of the invention, to have device 1 and the various positioning elements actuated by sensors (positional) and movement of the various elements of the device control by servo-motors, a microprocessor, and the like (e.g., computer controlled). It is appreciated that placement of the prosthesis V may be more precisely controlled through computer control and mechanical movement of the various elements of device.
Notably, the deployment elements 10, 20 are actuatable entirely independently of each other. This gives the operator complete freedom in selecting which of the portions IF, OF to deploy first according to the specific implantation method or conditions.
In
Such appropriate positioning includes both axial positioning (i.e. avoiding deploying the prosthetic valve V too far “upstream” or too far “downstream” of the desired position with the ensuing negative effect that the inflow end IF is not correctly positioned with respect to the valve annulus A) and radial positioning. The sinuses of Valsalva are configured as a hollow, three-lobed structure. Accordingly, accurately positioning each formation P of the prosthesis V in a respective sinus of Valsalva will ensure the correct positioning or angular orientation of the prosthetic valve as a whole, which will ensure that the leaflets of the prosthetic valve are correctly oriented (i.e., extend at the angular positions of the annulus where the natural valve leaflets were located before removal).
In exemplary embodiments, the instrument 1 may further include various structures or features to assist the operator in obtaining the appropriate axial positioning with respect to the aortic annulus and radial positioning with respect to the sinuses of Valsalva. The instrument 1 (or the guide catheter or delivery tube), for example may include a lumen sufficient to allow the injection of contrast fluid to a location at the implantation site. For the embodiment shown in
In one exemplary embodiment (e.g., in the case of “sutureless” implantation), the carrier portion 2 and the prosthesis V may be arranged from the beginning in the configuration represented in
It will also be appreciated that from the configuration shown in
Next, the prosthetic implantation process progresses by sliding the deployment element 10 so that it releases the outflow annular portion OF. The portion OF can then radially expand against the aortic wall, thus completing the second phase of the implantation operation of the prosthesis V.
Finally, as shown in
According to another exemplary embodiment, the instrument 1 can be adapted such that substantially oxygen-free environment can be maintained through out the valve implantation procedure. According to one embodiment, the instrument can include a seal or one or more pressure sensors and/or regulators for maintaining a constant flow a fluid, such as saline, or a constant pressure of CO2 at the implantation site through the delivery instrument 1 in order to minimize and/or prevent air embolism during the procedure.
After withdrawing the deployment element 10, so as to release the formations P (
Subsequently, by completely withdrawing in a proximal direction the deployment element 10, the operator releases the annular inflow portion IF that is thus deployed in correspondence with the aortic valve annulus thus completing the two-step implantation procedure of the prosthetic valve V (see
The implantation procedure then proceeds, as schematically represented in
The teaching provided in
This technique may be useful to avoid movement or “jumping” of the prosthesis V during implantation. For instance, if the operator fears that deployment of the inflow end portion IF in correspondence of the aortic annulus A may give rise to an undesired longitudinal displacement of the valve prosthesis V as a whole, while the inflow portion IF is being released by the element 10 and expands to engage the aortic annulus A, a post-expansion balloon 7 associated with the outflow end OF can be inflated. In this way, as long as the post-expansion balloon 7 is kept dilated, the outflow end OF is urged and thus safely anchored to the lumen wall and any undesired displacement of the prosthetic valve V in an axial direction is prevented. Once the inflow portion IF is safely positioned at the aortic annulus A, the balloon 7 can be deflated and the instrument 1 withdrawn.
Other embodiments of the present invention include “hybrid” solutions, where a cardiac valve prosthesis V includes one or more self-expandable portions (having associated deployment elements 10, 20 of the type illustrated in
In one variant and in the case where expansion due to a positive action of one or more balloons is preferred over the use of a self-expandable portion, the same balloon may be used both as an expansion balloon (
As schematically illustrated in
In yet another variant of the invention, the elements 10, 20 are formed of a material that permits them to collapse after deployment of the prosthesis V. It is appreciated that this permits the entire device to be more easily removed from the subject.
In this exemplary embodiment, the locking member 22 takes the form of a hub positioned at the distal end of a tubular member 23 having the wire 21 slidably arranged therein. The sheath 11 surrounds the tubular member 23 and is adapted to slide thereon so that the locking member 22 is capable of maintaining at a fixed axial position (e.g. via end flanges 220) the annular outflow portion OF with which the locking member is associated. The annular end portion in question is thus prevented from sliding axially of the deployment element 20, at least as long as the annular end portion OF is radially constrained by the deployment element 20.
The arrangement described makes it possible to adjust the position of the annular end portion locked by the locking member (and the position of the valve prosthesis V as a whole) both axially and angularly to the implantation site. This applies more or less until the annular portion expands to the point where further displacement is prevented by engagement of the annular portion with the valve annulus or the aortic wall. Additionally, the presence of the locking member(s) 22 facilitates possible recovery of the prosthetic valve V in case the implantation procedure is to be aborted.
According to various embodiments of the present invention, the delivery system is capable of both antegrade and retrograde delivery of instruments and the like. One exemplary embodiment of such a delivery system is disclosed in co-pending, commonly assigned U.S. patent application Ser. No. 11/851,523,filed on Sep. 7, 2007,entitled “Prosthetic Valve Delivery System Including Retrograde/Antegrade Approach,” which is hereby incorporated by reference in its entirety.
Using techniques well known to those of skill in the art, access to the heart 102, according to some embodiments, is established percutaneously through the aorta, femoral, radial or brachial arteries using a retrograde approach to reach a target site within the heart 106 (e.g. the aorta 1054 or aortic valve annulus 1010). Likewise, according to some embodiments, access to the aortic valve annulus is accomplished using a retrograde, minimally-invasive surgical technique to provide access to the aortic valve annulus 1010 through an opening in the aortic arch.
Alternatively, according to various embodiments, access to the heart 102 and the aortic valve annulus 1010 is established through the apical area 1060 (e.g., apex) of the heart. In these embodiments, a percutaneous access port may be established through a patient's chest wall and into the left ventricle at or near the apex 1060. According to some embodiments, access to the left ventricle 1050 through the apex 1060 is established using one of the methods and devices generally shown and described in U.S. Pat. No. 6,010,531,entitled “Less-invasive Devices and Methods for Cardiac Valve Surgery”, which is incorporated herein by reference.
The apex 1060 of the heart 102 is generally the blunt rounded inferior extremity of the heart 102 formed by the left and right ventricles, 1026 and 1050. In normal healthy humans, the apex 1060 generally lies behind the fifth left intercostal space from the mid-sternal line. Access to the valve annulus 1010 through the apex 1060 can be established using a larger diameter access port than is possible using percutaneous access methods. Thus, apical access to the heart 102 permits greater flexibility with respect to the types of devices and surgical methods that may be performed in the heart and great vessels.
According to the embodiment of
The implantation device 1074 is of sufficient size and length to pass through a first opening in a patient's body (e.g., an aorta or a femoral artery access point), through a patient's aorta 1054, and to exit through an access port 1076 established in a patient's left ventricle 1050 at or near the apex 1060. The implantation device 1074 then extends through a transthoracic port 1078, which provides access through the patient's thoracoabdominal (e.g., intercostal) region and into the left ventricle 1050 at or near the apex 1060. The transthoracic port according to various exemplary embodiments is one of an introducer, trocar, or cannula, as is generally known in the art. According to one exemplary embodiment of the present invention, the port 1078 includes one or more hemostasis valves or seals. The hemostasis valve or seal is adapted to provide a blood tight seal against any blood loss or leakage during the procedure, and can be used at the apex, at the aorta, or in both locations. The port 1078 is configured to allow passage of the implantation device, catheter, or any tools or devices to be delivered to the target site using the implantation device, while at the same time providing a blood tight seal against blood loss or leakage.
According to one exemplary technique for introducing the access system 1070, a physician establishes an access port into the patient's aorta or femoral artery using any of a variety of well-known techniques. The physician then establishes a second access point in the patient's intercostal region using the port 1078. Using known imaging and guidance techniques, the physician then advances the implantation device 1074 through the patient's aorta or arterial system to the aortic valve annulus 1010. The physician then advances the implantation device 1074 across the aortic valve annulus 1010, through the left ventricle 1050, and out of the heart through the port 1078. At this point, the physician has established a continuous pathway allowing both retrograde (i.e., through the aorta or aortic arch) and antegrade (i.e., through the apex 1060) access to the aortic valve annulus 1010.
According to another exemplary embodiment, the implantation device 1074 includes two portions. The physician introduces a first portion through the aorta or femoral artery to the aortic valve annulus 1010 and introduces a second portion through the apex 1060. According to various embodiments, the physician then couples the two portions together at or near the valve annulus 1010 or the aortic root. In these embodiments, the implantation device 1074 includes any of a variety of known structures for coupling the free ends to one another, so as to form a continuous rail or track. According to other embodiments, the physician employs any of a numerous variety of techniques known in the art to introduce the implantation device 1074. According to various embodiments, the physician employs one or more of the following techniques to implant the device 1074: optionally ballooning the native valve in one variant of the invention, or removing the native valve (e.g., by cutting the valve out of the annulus), optionally using an umbrella capture feature to catch any debris that may result from the cut, and implanting the device 1074.
Once introduced, the implantation device 1074 establishes a pathway between a first opening and second opening in a patient's body. The implantation device is left in place within the heart 102 to provide a tether or “rail” over which other tools or devices may be delivered. Additional tools and devices may be delivered along the rail using either a retrograde (i.e., via the aorta) or an antegrade (i.e., via the apex and left ventricle) approach. The implantation device 1074 allows for one or more than one device to be delivered to the target site at the same time or substantially at the same time. This feature allows flexibility in delivery options and may increase the speed in the successive steps in the valve replacement procedure.
By way of further example, one tool or set of tools can be delivered through the access port from the aorta while a second tool or set of tools can be delivered through the access point in the left ventricle, along a single track spanning both points of access or along separate tracks, one for each access point. An aortic valve (which can be stenotic in many patients) cutter or remover is delivered through the access point in the aorta by a first physician or technician. The native stenotic valve (e.g., aortic valve) is excised, stored in a chamber of the cutter, and then the cutter assembly is removed through the aortic access point. A delivery system for an expandable valve prosthesis can be guided through the ventricular access port and be positioned in the ventricle ready for immediate insertion into position once the cutting operation has been completed. The delivery system can be optionally operated by a second physician or technician and be ready and waiting for deployment. It is appreciated that the speed with which both the cutting and the valve prosthesis deployment operations is greatly increased and the procedure time is greatly reduced using a combination antegrade and retrograde delivery approach. In this way the hemodynamic blood flow for the patient is maintained at an acceptable level while the patient is off-pump or partially off-pump. Similarly, it is appreciated that a variety of tools or modules (or portions thereof) can be guided either antegrade or retrograde along the guidewire.
In various exemplary embodiments of the invention, the cutter or native valve leaflet remover is sized and dimensioned to be delivered through the apex of the heart, while the delivery system including a heart valve prosthesis is sized and dimensioned for delivery through an access point on the aorta. In yet another variant of the invention, an access point can be established at any suitable point in the aortal tree.
By way of further example, a top portion of the cutter can be guided into cutting position along the guidewire along from the aortic access point, while a bottom portion of a cutter can be guided along the guidewire through the access point in the ventricle. The two portions meet at the native valve and perform the cutting and removal operation and then are each removed through the same access areas where they entered the patient.
By way of further example, other modules that can travel along the guidewire can include pumps for assisting in maintaining the patient's hemodynamic flow. The pumps can be positioned in various locations along the guidewire as needed. Other modules (e.g., a cutter or prosthesis delivery module) can then be guided over the pumps to perform their required operations.
As described, the valve access system 1070 allows for delivery of a variety of devices to or near the aortic valve annulus 1010. The system 1070 may be used for example to introduce any of a variety of prosthetic heart valves, including, for example, stented and stentless tissue valves. The system 1070 may also be used to introduce an imaging system to view all or a portion of a procedure. Imaging systems are well-known in the art and include, for example, transesophageal echo, transthoracic echo, intravascular ultrasound imaging (IVUS), and/or a radiopaque dye or contrast fluid. The imaging system may also include an optical viewing device, such as a fiber-optic camera.
The valve access system 1070 allows for delivery of a variety of additional tools or devices, including, for example, the following: leaflet excision tools, leaflet capture devices, imaging devices, prosthetic heart valves, prosthetic valve delivery systems, blood-pump devices, inflation catheters and balloons, debris capture collapsible and expandable umbrellas, stenotic tissue debridement tools, markers located on the guidewire to assist in location of the guidewire at the appropriate location, centering balloons to center the guidewire in the desired orientation, and the like. In yet a further variant, an anti-embolization module is also added. According to various embodiments, the leaflet excision module includes a rigid portion having an actuator exerting sufficient force to cut through a calcified leaflet.
According to another embodiment of the present invention, the valve access system includes one or more interchangeable modules that are configured to be delivered along the implantation device 1074 to the valve annulus 1010. The implantation device 1074 permits one or more modules to be in use at a given time, in series or in parallel. Depending upon the size of the module, an antegrade, retrograde, or combination antegrade and retrograde delivery approach may be chosen. As the apex 1060 is not limited by the size constraints which are presented by percutaneous surgical methods, larger modules or devices may be delivered through the port 1078. Smaller modules may continue to be delivered through the femoral artery approach or directly through a port or incision in the aorta. Ultimately either approach may be chosen at the discretion of one of skill in the art performing the procedure.
In yet another embodiment of the invention, all modules are de-aired, filled with a fluid (e.g., saline), or filled with an appropriate gas (e.g., carbon dioxide or nitrogen) prior to use. This process eliminates the risk of an embolism occurring through the introduction of any of the modules described below directly into the beating heart of the subject. According to various embodiments, the modules are de-aired using one of the techniques described in co-pending, commonly assigned U.S. patent application Ser. No. 11/851,528,filed on Sep. 7, 2007,entitled “Fluid-Filled Delivery System for in Situ Deployment of Cardiac Valve Prostheses,” which is hereby incorporated by reference in its entirety.
According to the embodiment of the present invention shown in
According to yet a further embodiment of the present invention, as is also shown in
According to yet a further embodiment of the present invention, as shown in
In yet another variant of the invention, two distinct mechanically unconnected tracks are used upon which two mechanically unconnected modules are utilized. In this variant, a first module is configured to be delivered from a first opening in a patient's aortic tree and through the patient's aorta. One or more of the modules described herein may be used. A second module is configured to be delivered through an opening in a ventricle. Again, one or more modules described herein may be used. As with the other embodiments described herein, the fact that two simultaneous or nearly simultaneous access points are used on the patient allows for speed of native valve removal and implantation of a new prosthesis.
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
This application is a continuation of U.S. application Ser. No. 11/851,528, now U.S. Pat. No. 8,114,154, and U.S. application Ser. No. 11/851,523, both filed Sep. 7, 2007, both of which are herein incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3671979 | Moulopoulos | Jun 1972 | A |
4011947 | Sawyer | Mar 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4477930 | Totten et al. | Oct 1984 | A |
4601706 | Aillon | Jul 1986 | A |
4624822 | Arru et al. | Nov 1986 | A |
4684364 | Sawyer et al. | Aug 1987 | A |
4722725 | Sawyer et al. | Feb 1988 | A |
4732152 | Wallsten et al. | Mar 1988 | A |
4758151 | Arru et al. | Jul 1988 | A |
4777951 | Cribier | Oct 1988 | A |
4784644 | Sawyer et al. | Nov 1988 | A |
4994077 | Dobben | Feb 1991 | A |
5057092 | Webster, Jr. | Oct 1991 | A |
5084151 | Vallana et al. | Jan 1992 | A |
5123919 | Sauter et al. | Jun 1992 | A |
5133845 | Vallana et al. | Jul 1992 | A |
5181911 | Shturman | Jan 1993 | A |
5201757 | Heyn et al. | Apr 1993 | A |
5287848 | Cubb et al. | Feb 1994 | A |
5304189 | Goldberg et al. | Apr 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5370684 | Vallana et al. | Dec 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5387247 | Vallana et al. | Feb 1995 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5423886 | Arru et al. | Jun 1995 | A |
5445646 | Euteneuer et al. | Aug 1995 | A |
5545214 | Stevens | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5556414 | Turi | Sep 1996 | A |
5662712 | Pathak et al. | Sep 1997 | A |
5693083 | Baker et al. | Dec 1997 | A |
5766151 | Valley et al. | Jun 1998 | A |
5772693 | Brownlee | Jun 1998 | A |
5782811 | Samson et al. | Jul 1998 | A |
5824064 | Taheri | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5849005 | Garrison et al. | Dec 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5871489 | Ovil | Feb 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5951600 | Lemelson | Sep 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5980570 | Simpson | Nov 1999 | A |
6010530 | Goicoechea | Jan 2000 | A |
6010531 | Donlon et al. | Jan 2000 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6030360 | Biggs | Feb 2000 | A |
6090099 | Samson et al. | Jul 2000 | A |
6106497 | Wang | Aug 2000 | A |
6125852 | Stevens et al. | Oct 2000 | A |
6139572 | Campbell et al. | Oct 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6251093 | Valley et al. | Jun 2001 | B1 |
6299638 | Sauter | Oct 2001 | B1 |
6309382 | Garrison et al. | Oct 2001 | B1 |
6346071 | Mussivand | Feb 2002 | B1 |
6402780 | Williamson, IV et al. | Jun 2002 | B2 |
6416474 | Penner et al. | Jul 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6572642 | Rinaldi et al. | Jun 2003 | B2 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6607553 | Healy et al. | Aug 2003 | B1 |
6641558 | Aboul-Hosn et al. | Nov 2003 | B1 |
6645197 | Garrison et al. | Nov 2003 | B2 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6685739 | DiMatteo et al. | Feb 2004 | B2 |
6726648 | Kaplon et al. | Apr 2004 | B2 |
6726712 | Raeder-Devens et al. | Apr 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6767362 | Schreck | Jul 2004 | B2 |
6769434 | Liddicoat et al. | Aug 2004 | B2 |
6805711 | Quijano et al. | Oct 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6830585 | Artof et al. | Dec 2004 | B1 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6913618 | Denardo et al. | Jul 2005 | B2 |
6945957 | Freyman | Sep 2005 | B2 |
6964673 | Tsugita et al. | Nov 2005 | B2 |
6974464 | Quijano et al. | Dec 2005 | B2 |
6981942 | Khaw et al. | Jan 2006 | B2 |
6991646 | Clerc et al. | Jan 2006 | B2 |
7001423 | Euteneuer et al. | Feb 2006 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7018408 | Bailey et al. | Mar 2006 | B2 |
7041132 | Quijano et al. | May 2006 | B2 |
7044966 | Svanidze et al. | May 2006 | B2 |
7077801 | Haverich | Jul 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7144364 | Barbut et al. | Dec 2006 | B2 |
7156872 | Strecker | Jan 2007 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7201761 | Woolfson et al. | Apr 2007 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7338467 | Lutter | Mar 2008 | B2 |
7338520 | Bailey et al. | Mar 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
RE40377 | Williamson, IV et al. | Jun 2008 | E |
7399315 | Iobbi | Jul 2008 | B2 |
7544206 | Cohn | Jun 2009 | B2 |
7556646 | Yang et al. | Jul 2009 | B2 |
7618432 | Pedersen et al. | Nov 2009 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7993392 | Rihhini et al. | Aug 2011 | B2 |
8057539 | Ghione et al. | Nov 2011 | B2 |
8070799 | Righini et al. | Dec 2011 | B2 |
20010002445 | Vesely | May 2001 | A1 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010010017 | Letac et al. | Jul 2001 | A1 |
20010039450 | Pavcnik et al. | Nov 2001 | A1 |
20010044591 | Stevens et al. | Nov 2001 | A1 |
20020029075 | Leonhardt | Mar 2002 | A1 |
20020045846 | Kaplon et al. | Apr 2002 | A1 |
20020058995 | Stevens | May 2002 | A1 |
20020099431 | Armstrong et al. | Jul 2002 | A1 |
20020107531 | Schreck et al. | Aug 2002 | A1 |
20020117264 | Rinaldi et al. | Aug 2002 | A1 |
20020123802 | Snyders | Sep 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020198594 | Schreck | Dec 2002 | A1 |
20030014104 | Cribier | Jan 2003 | A1 |
20030023300 | Bailey et al. | Jan 2003 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030033000 | DiCaprio et al. | Feb 2003 | A1 |
20030036795 | Andersen et al. | Feb 2003 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030109924 | Cribier | Jun 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030153974 | Spenser et al. | Aug 2003 | A1 |
20030163194 | Quijano et al. | Aug 2003 | A1 |
20030191521 | Denardo et al. | Oct 2003 | A1 |
20030191528 | Quijano et al. | Oct 2003 | A1 |
20040034411 | Quijano et al. | Feb 2004 | A1 |
20040039371 | Tockman et al. | Feb 2004 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040039442 | St. Goar et al. | Feb 2004 | A1 |
20040049266 | Anduiza et al. | Mar 2004 | A1 |
20040055606 | Hendricksen et al. | Mar 2004 | A1 |
20040078072 | Tu et al. | Apr 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040093063 | Wright et al. | May 2004 | A1 |
20040106976 | Bailey et al. | Jun 2004 | A1 |
20040127848 | Freyman | Jul 2004 | A1 |
20040147993 | Westlund et al. | Jul 2004 | A1 |
20040186563 | Lobbi | Sep 2004 | A1 |
20040215333 | Duran et al. | Oct 2004 | A1 |
20040236170 | Kim | Nov 2004 | A1 |
20040249413 | Allen et al. | Dec 2004 | A1 |
20050075584 | Cali | Apr 2005 | A1 |
20050075712 | Biancucci et al. | Apr 2005 | A1 |
20050075713 | Biancucci et al. | Apr 2005 | A1 |
20050075717 | Nguyen et al. | Apr 2005 | A1 |
20050075718 | Nguyen et al. | Apr 2005 | A1 |
20050075719 | Bergheim | Apr 2005 | A1 |
20050075720 | Nguyen et al. | Apr 2005 | A1 |
20050075724 | Svanidze et al. | Apr 2005 | A1 |
20050075726 | Svanidze et al. | Apr 2005 | A1 |
20050075728 | Nguyen et al. | Apr 2005 | A1 |
20050075729 | Nguyen et al. | Apr 2005 | A1 |
20050075730 | Myers et al. | Apr 2005 | A1 |
20050075731 | Artof et al. | Apr 2005 | A1 |
20050080476 | Gunderson et al. | Apr 2005 | A1 |
20050096993 | Pradhan et al. | May 2005 | A1 |
20050104957 | Okamoto et al. | May 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137689 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Salahieh et al. | Jun 2005 | A1 |
20050137693 | Haug et al. | Jun 2005 | A1 |
20050137694 | Salahieh et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137696 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050137698 | Salahieh et al. | Jun 2005 | A1 |
20050137699 | Salahieh et al. | Jun 2005 | A1 |
20050137701 | Salahieh et al. | Jun 2005 | A1 |
20050137702 | Haug et al. | Jun 2005 | A1 |
20050143809 | Salahieh et al. | Jun 2005 | A1 |
20050165480 | Jordan et al. | Jul 2005 | A1 |
20050197695 | Stacchino et al. | Sep 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050251251 | Cribier | Nov 2005 | A1 |
20050267493 | Schreck et al. | Dec 2005 | A1 |
20060004436 | Amarant et al. | Jan 2006 | A1 |
20060004439 | Spenser et al. | Jan 2006 | A1 |
20060020333 | Lashinski et al. | Jan 2006 | A1 |
20060020334 | Lashinski et al. | Jan 2006 | A1 |
20060025844 | Majercak et al. | Feb 2006 | A1 |
20060030922 | Dolan | Feb 2006 | A1 |
20060063199 | Elgebaly et al. | Mar 2006 | A1 |
20060064054 | Sakakine et al. | Mar 2006 | A1 |
20060074271 | Cotter | Apr 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060085060 | Campbell | Apr 2006 | A1 |
20060095025 | Levine et al. | May 2006 | A1 |
20060100639 | Levin et al. | May 2006 | A1 |
20060135962 | Kick et al. | Jun 2006 | A1 |
20060142838 | Molaei et al. | Jun 2006 | A1 |
20060142848 | Gabbay | Jun 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060195134 | Crittenden | Aug 2006 | A1 |
20060195184 | Lane et al. | Aug 2006 | A1 |
20060229659 | Gifford et al. | Oct 2006 | A1 |
20060241656 | Starksen et al. | Oct 2006 | A1 |
20060271081 | Realyvasquez | Nov 2006 | A1 |
20060276775 | Rosenberg et al. | Dec 2006 | A1 |
20070010850 | Balgobin et al. | Jan 2007 | A1 |
20070027534 | Bergheim et al. | Feb 2007 | A1 |
20070032850 | Ruiz et al. | Feb 2007 | A1 |
20070055357 | Pokorney et al. | Mar 2007 | A1 |
20070088431 | Bourang et al. | Apr 2007 | A1 |
20070100302 | Dicarlo et al. | May 2007 | A1 |
20070100356 | Lucatero et al. | May 2007 | A1 |
20070100440 | Figulla et al. | May 2007 | A1 |
20070112355 | Salahieh et al. | May 2007 | A1 |
20070112422 | Dehdashtian | May 2007 | A1 |
20070118207 | Amplatz et al. | May 2007 | A1 |
20070118209 | Strecker | May 2007 | A1 |
20070162100 | Gabbay | Jul 2007 | A1 |
20070162103 | Case et al. | Jul 2007 | A1 |
20070162107 | Haug et al. | Jul 2007 | A1 |
20070162111 | Fukamachi et al. | Jul 2007 | A1 |
20070162113 | Sharkawy et al. | Jul 2007 | A1 |
20070173861 | Strommer et al. | Jul 2007 | A1 |
20070203503 | Salahieh et al. | Aug 2007 | A1 |
20070203561 | Forster et al. | Aug 2007 | A1 |
20070203575 | Forster et al. | Aug 2007 | A1 |
20070219630 | Chu | Sep 2007 | A1 |
20070250097 | Weitzner et al. | Oct 2007 | A1 |
20070265702 | Lattouf | Nov 2007 | A1 |
20080021546 | Patz et al. | Jan 2008 | A1 |
20080065011 | Marchand et al. | Mar 2008 | A1 |
20080082165 | Wilson et al. | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147160 | Ghione et al. | Jun 2008 | A1 |
20080147180 | Ghione et al. | Jun 2008 | A1 |
20080147181 | Ghione et al. | Jun 2008 | A1 |
20080147182 | Righini et al. | Jun 2008 | A1 |
20080147188 | Steinberg | Jun 2008 | A1 |
20080183097 | Leyde et al. | Jul 2008 | A1 |
20080208216 | Cerier | Aug 2008 | A1 |
20080262507 | Righini et al. | Oct 2008 | A1 |
20090069886 | Suri et al. | Mar 2009 | A1 |
20090069887 | Righini et al. | Mar 2009 | A1 |
20090069889 | Suri et al. | Mar 2009 | A1 |
20090105794 | Ziarno et al. | Apr 2009 | A1 |
20090118580 | Sun et al. | May 2009 | A1 |
20090157174 | Yoganathan et al. | Jun 2009 | A1 |
20090164004 | Cohn | Jun 2009 | A1 |
20090164006 | Seguin et al. | Jun 2009 | A1 |
20090171363 | Chocron | Jul 2009 | A1 |
20090171456 | Kveen et al. | Jul 2009 | A1 |
20090177275 | Case | Jul 2009 | A1 |
20090228093 | Taylor et al. | Sep 2009 | A1 |
20090234443 | Ottma et al. | Sep 2009 | A1 |
20090240326 | Wilson et al. | Sep 2009 | A1 |
20090254165 | Tabor et al. | Oct 2009 | A1 |
20090281609 | Benichou et al. | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100292782 | Giannetti | Nov 2010 | A1 |
20100292783 | Giannetti | Nov 2010 | A1 |
20100292784 | Giannetti | Nov 2010 | A1 |
20120053684 | Righini | Mar 2012 | A1 |
Number | Date | Country |
---|---|---|
19546692 | Jun 1997 | DE |
19857887 | Jul 2000 | DE |
0155245 | May 1990 | EP |
0592410 | Oct 1995 | EP |
0512359 | Dec 1996 | EP |
0515324 | Dec 1996 | EP |
0133420 | Feb 1998 | EP |
0850607 | Jul 1998 | EP |
1057460 | Dec 2000 | EP |
1088529 | Apr 2001 | EP |
1356763 | Oct 2003 | EP |
1356793 | Oct 2003 | EP |
0852481 | Feb 2004 | EP |
1440671 | Jul 2004 | EP |
955895 | Aug 2005 | EP |
1488735 | Jun 2007 | EP |
1212989 | Jan 2008 | EP |
1653884 | Jun 2008 | EP |
1935377 | Jun 2008 | EP |
1955643 | Aug 2008 | EP |
1570809 | Jan 2009 | EP |
2033581 | Mar 2009 | EP |
2033597 | Mar 2009 | EP |
2828091 | Feb 2003 | FR |
9724989 | Jul 1997 | WO |
9817202 | Apr 1998 | WO |
9829057 | Jul 1998 | WO |
WO 9904728 | Feb 1999 | WO |
9956665 | Nov 1999 | WO |
WO 0018303 | Apr 2000 | WO |
0041652 | Jul 2000 | WO |
WO 0041525 | Jul 2000 | WO |
WO 0121244 | Mar 2001 | WO |
0162189 | Aug 2001 | WO |
0164137 | Sep 2001 | WO |
0176510 | Oct 2001 | WO |
0241789 | May 2002 | WO |
0247575 | Jun 2002 | WO |
02076348 | Oct 2002 | WO |
03003943 | Jan 2003 | WO |
03094797 | Nov 2003 | WO |
2004089253 | Oct 2004 | WO |
WO 2005046525 | May 2005 | WO |
WO 2005065200 | Jul 2005 | WO |
2005104957 | Oct 2005 | WO |
WO 2005096993 | Oct 2005 | WO |
WO2005096993 | Oct 2005 | WO |
2006054107 | May 2006 | WO |
2006063199 | Jun 2006 | WO |
WO 2006086135 | Aug 2006 | WO |
2006116558 | Nov 2006 | WO |
WO 2006135551 | Dec 2006 | WO |
WO 2006138173 | Dec 2006 | WO |
WO 2007071436 | Jun 2007 | WO |
WO 2007076463 | Jul 2007 | WO |
WO 2008097589 | Aug 2008 | WO |
WO 2008125153 | Oct 2008 | WO |
Entry |
---|
European Search Report issued in EP Application No. 08159301, mailed Dec. 30, 2008, 6 pages. |
Partial European Search Report issued in EP Application No. 10155332, dated Jun. 9, 2011, 7 pages. |
European Search Report and Search Opinion of European Patent Application No. 06126556.7, dated Jun. 27, 2007. |
European Search Report and Search Opinion of European Patent Application No. 07115960.2, dated Jan. 24, 2008. |
Huber et al., “Direct-Access Valve Replacement: A Novel Approach for Off-Pump Valve Implantation Using Valved Stents,” Journal of the American College of Cardiology, 46(2): 366-370, Jul. 19, 2002. |
U.S. Appl. No. 11/851,523, filed Sep. 7, 2007. |
U.S. Appl. No. 11/851,528, filed Sep. 7, 2007. |
European Search Report Issued in EP Application No. 09160183, dated Oct. 2, 2009, 6 pages. |
European Search Report Issued in EP Application No. 09160186, dated Oct. 6, 2009, 5 pages. |
European Search Report Issued in EP Application No. 07115951, dated Sep. 24, 2009, 8 pages. |
Extended European Search Report issued in EP Application 06126552, dated Jun. 6, 2007, 7 pages. |
Extended European Search Report issued in EP Application 09158822, dated Sep. 9, 2009, 5 pages. |
Ho, Paul C., “Percutaneous aortic valve replacement: A novel design of the delivery and deployment system”, Minimally Invasive Therapy, 2008; 17:3; 190-194. |
Partial European Search Report issued in EP App No. 06126556, mailed Apr. 16, 2007, 6 pages. |
Extended European Search Report issued in EP Application 06126556, dated Jul. 6, 2007, 13 pages. |
Huber et al., “Direct-Access Valve Replacement: A Novel Approach for Off-Pump Valve Implantation Using Valved Stents”, Journal for the American College of Cardiology, pp. 366-370, vol. 46, No. 2, Jul. 19, 2005, ISSN: 0735-1097/05, published on-line Jul. 5, 2005. |
European Search Report issued in EP Application 08163752, dated Dec. 29, 2008. |
European Search Report Issued in EP 09160184 dated Oct. 22, 2009. |
Number | Date | Country | |
---|---|---|---|
20090069890 A1 | Mar 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11851528 | Sep 2007 | US |
Child | 12147560 | US | |
Parent | 11851523 | Sep 2007 | US |
Child | 11851528 | US |